281 related articles for article (PubMed ID: 36008934)
1. Tumor-Promoting ATAD2 and Its Preclinical Challenges.
Liu H; Wen Q; Yan S; Zeng W; Zou Y; Liu Q; Zhang G; Zou J; Zou X
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008934
[No Abstract] [Full Text] [Related]
2. Emerging oncogene ATAD2: Signaling cascades and therapeutic initiatives.
Nayak A; Dutta M; Roychowdhury A
Life Sci; 2021 Jul; 276():119322. PubMed ID: 33711386
[TBL] [Abstract][Full Text] [Related]
3. ATAD2 in cancer: a pharmacologically challenging but tractable target.
Hussain M; Zhou Y; Song Y; Hameed HMA; Jiang H; Tu Y; Zhang J
Expert Opin Ther Targets; 2018 Jan; 22(1):85-96. PubMed ID: 29148850
[TBL] [Abstract][Full Text] [Related]
4. Coordination of Di-Acetylated Histone Ligands by the ATAD2 Bromodomain.
Evans CM; Phillips M; Malone KL; Tonelli M; Cornilescu G; Cornilescu C; Holton SJ; Gorjánácz M; Wang L; Carlson S; Gay JC; Nix JC; Demeler B; Markley JL; Glass KC
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502039
[TBL] [Abstract][Full Text] [Related]
5. ATAD2 drives colorectal cancer progression by regulating TRIM25 expression via a positive feedback loop with E2F transcriptional factors.
Tong Y; Li J; Peng M; Qian Q; Shi W; Chen Z; Liu B
Biochem Biophys Res Commun; 2022 Feb; 594():146-152. PubMed ID: 35085891
[TBL] [Abstract][Full Text] [Related]
6. ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target.
Fu J; Zhang J; Chen X; Liu Z; Yang X; He Z; Hao Y; Liu B; Yao D
Theranostics; 2023; 13(2):787-809. PubMed ID: 36632213
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach.
Miller DC; Martin MP; Adhikari S; Brennan A; Endicott JA; Golding BT; Hardcastle IR; Heptinstall A; Hobson S; Jennings C; Molyneux L; Ng Y; Wedge SR; Noble MEM; Cano C
Org Biomol Chem; 2018 Mar; 16(11):1843-1850. PubMed ID: 29469144
[TBL] [Abstract][Full Text] [Related]
8. ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication.
Koo SJ; Fernández-Montalván AE; Badock V; Ott CJ; Holton SJ; von Ahsen O; Toedling J; Vittori S; Bradner JE; Gorjánácz M
Oncotarget; 2016 Oct; 7(43):70323-70335. PubMed ID: 27612420
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic potential of ATAD2 in stomach cancer and insights into the protein-protein interactions at its AAA + ATPase domain and bromodomain.
Nayak A; Kumar S; Singh SP; Bhattacharyya A; Dixit A; Roychowdhury A
J Biomol Struct Dyn; 2022 Aug; 40(12):5606-5622. PubMed ID: 33438526
[TBL] [Abstract][Full Text] [Related]
10. Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain.
Gay JC; Eckenroth BE; Evans CM; Langini C; Carlson S; Lloyd JT; Caflisch A; Glass KC
Proteins; 2019 Feb; 87(2):157-167. PubMed ID: 30520161
[TBL] [Abstract][Full Text] [Related]
11. The association between bromodomain proteins and cancer stemness in different solid tumor types.
Czerwinska P; Jaworska AM; Wlodarczyk NA; Cisek M; Karwacka M; Lipowicz J; Ostapowicz J; Rosochowicz M; Mackiewicz AA
Int J Cancer; 2022 Jun; 150(11):1838-1849. PubMed ID: 35049055
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma.
Wang XL; Wang S; Wu ZZ; Yang QC; Li H; Xiong HG; Wan SC; Sun ZJ
Int J Med Sci; 2020; 17(11):1598-1609. PubMed ID: 32669963
[TBL] [Abstract][Full Text] [Related]
13. Effect of chronic intermittent hypoxia-induced HIF-1α/ATAD2 expression on lung cancer stemness.
Hao S; Li F; Jiang P; Gao J
Cell Mol Biol Lett; 2022 Jun; 27(1):44. PubMed ID: 35672694
[TBL] [Abstract][Full Text] [Related]
14. Fragment-based design, synthesis and biological evaluation of theophylline derivatives as ATAD2 inhibitors in BT-549 cells.
Yao D; You J; Yang X; Zhang J; Yao X
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2242601. PubMed ID: 37533352
[TBL] [Abstract][Full Text] [Related]
15. Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNA‑damaging chemotherapy agents and radiation.
Duan Z; Andrews NP; Chen CZ; Fan M; Wang J; Shen J; Li JJ; Chen HW
Oncol Rep; 2020 Jan; 43(1):318-327. PubMed ID: 31789405
[TBL] [Abstract][Full Text] [Related]
16. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
Liu Q; Liu H; Li L; Dong X; Ru X; Fan X; Wen T; Liu J
Int J Oncol; 2020 Jan; 56(1):219-231. PubMed ID: 31746426
[TBL] [Abstract][Full Text] [Related]
17. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
18. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
Zhou L; Yang C; Zhang N; Zhang X; Zhao T; Yu J
Biomed Pharmacother; 2020 May; 125():109964. PubMed ID: 32044716
[TBL] [Abstract][Full Text] [Related]
19. Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cells.
Morozumi Y; Boussouar F; Tan M; Chaikuad A; Jamshidikia M; Colak G; He H; Nie L; Petosa C; de Dieuleveult M; Curtet S; Vitte AL; Rabatel C; Debernardi A; Cosset FL; Verhoeyen E; Emadali A; Schweifer N; Gianni D; Gut M; Guardiola P; Rousseaux S; Gérard M; Knapp S; Zhao Y; Khochbin S
J Mol Cell Biol; 2016 Aug; 8(4):349-62. PubMed ID: 26459632
[TBL] [Abstract][Full Text] [Related]
20. Structure of the human ATAD2 AAA+ histone chaperone reveals mechanism of regulation and inter-subunit communication.
Cho C; Ganser C; Uchihashi T; Kato K; Song JJ
Commun Biol; 2023 Sep; 6(1):993. PubMed ID: 37770645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
